title: Secondary EML4-ALK-positive lung adenocarcinoma in a patient previously treated for acute lymphoblastic leukemia in childhood: a case report.
abstract: It is widely recognized that the risk of secondary neoplasms increases as childhood cancer survivors progress through adulthood. These are mainly hematological malignancies, and recurrent chromosome translocations are commonly detected in such cases. On the other hand, while secondary epithelial malignancies have sometimes been reported, chromosome translocations in these epithelial malignancies have not. A 33-year-old man who had been diagnosed with acute lymphoblastic leukemia and treated with chemotherapy almost 20 years earlier was diagnosed with lung adenocarcinoma. After chromosomal rearrangement of echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene was detected in this adenocarcinoma, he responded to treatment with crizotinib. It was therefore concluded that this echinoderm microtubule-associated protein-like 4 gene-anaplastic lymphoma kinase gene-positive lung adenocarcinoma was a secondary epithelial malignancy.
authors.affiliation: Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki yi-nakamu@umin.ac.jp.
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Nakamura
authors.affiliation: Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki.
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Taniguchi
authors.affiliation: Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki.
authors.forename: Kosuke
authors.initials: K
authors.lastname: Mizoguchi
authors.affiliation: Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki.
authors.forename: Takaya
authors.initials: T
authors.lastname: Ikeda
authors.affiliation: Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki.
authors.forename: Kohei
authors.initials: K
authors.lastname: Motoshima
authors.affiliation: Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yamaguchi
authors.affiliation: Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki.
authors.forename: Seiji
authors.initials: S
authors.lastname: Nagashima
authors.affiliation: Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki.
authors.forename: Katsumi
authors.initials: K
authors.lastname: Nakatomi
authors.affiliation: Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
authors.forename: Manabu
authors.initials: M
authors.lastname: Soda
authors.affiliation: Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Mano
authors.affiliation: Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki.
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kohno
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D000077547:Crizotinib; D006801:Humans; D008175:Lung Neoplasms / Q000737:chemistry; D008297:Male; D058990:Molecular Targeted Therapy; D016609:Neoplasms, Second Primary / Q000188:drug therapy*; D015514:Oncogene Proteins, Fusion / Q000032:analysis*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D017741:Survivors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib
keywords: EML4–ALK; cancer survivor; secondary lung adenocarcinoma